Stellar
Biotechnologies, the world leader in the development, manufacture, and
commercialization of keyhole limpet hemocyanin (KLH), provided investors with a
complete overview of the company and initiatives underway. CEO Frank Oakes
explained how the company stands out in the biotechnology industry as the only
company dedicated solely to developing and commercializing KLH.
An
important immune-stimulating protein used in wide-ranging therapeutic and
diagnostic markets, KLH has a 40+ year track record of safe use in immunology.
This protein has been used in hundreds of clinical trials. Most importantly,
KLH has a number of high-value commercial pathways.
Eight
years of R&D have been invested in Stellar’s technology; funded by $7
million in NIH and NSF grants in addition to $23 million in equity funding. The
company’s multiple competitive advantages and strong head start put it far
ahead of any potential competitor.
During
one part of the call, Oaks showed investors a sample of the private companies,
research institutions, and global pharma companies that are using KLH in active
immune therapy trials. The extraordinary commercialization potential of this
protein was further revealed by the possible annual revenues that could be
generated from various indications such as rheumatoid arthritis ($200M),
Alzheimer’s ($200M), autoimmune diseases ($70-100M), infectious diseases ($100-150M),
and others.
The
question and answer session at the end of the call brought out even more
exciting aspects to consider when evaluating Steller Biotechnologies as an
investment. For instance, when responding to one investor’s question, Oakes
noted that Stellar benefits significantly from the fact that drug developers at
large pharma and boutique pharma companies have been doing the heavy lifting by
funding clinical trials that cost hundreds of millions of dollars to get drugs
through clinical development to commercialization.
To
learn more the significant milestones achieved in 2013 and the company’s plans
for expansion involving potential catalysts in R&D, manufacturing, and
business development, view the recorded webcast at http://dtg.fm/sbotf-call-12-2013.
For
more information on Stellar Biotechnologies, visit www.stellarbiotech.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
